Treatment of Factitious Hyperthyroidism in Subclinical Hyperthyroidism — Age Over 65 and High-Risk Comorbidities
Not all cases of subclinical hyperthyroidism require immediate intervention — but in patients aged over 65 or with certain comorbidities, watchful waiting is not sufficient. This protocol defines the treatment approach for this specific, higher-risk group.
Clinical Scenario
Subclinical hyperthyroidism is defined as suppressed serum TSH with normal free T4 and free T3 concentrations, confirmed on two readings three months apart.
Treatment is indicated when this biochemical pattern is present alongside age over 65 years, cardiac disease, osteoporosis, or a serum TSH below 0.1 mIU/L.
Treatment Approach
When treatment is warranted in this population, an interventional thyroid-directed approach is considered for persistent and progressive disease.
The structured protocol specifies which interventional option applies — and under what clinical circumstances — based on the underlying etiology and symptom profile. The full selection criteria and sequencing are available via the protocol.
Complete regimen and decision criteria available below.
References
DOI: 10.1089/thy.2016.0229
- Subclinical hyperthyroidism is defined as suppressed serum TSH with normal free T4 and free T3 concentrations in 2 readings done 3 months apart.
- Treatment should be considered in patients with subclinical hyperthyroidism who are either elderly (age >65 years old) OR with comorbidities (cardiac disease or osteoporosis) or TSH level <0.1mIU/L.
- Radioactive iodine therapy should be considered in those with persistent and progressive subclinical hyperthyroidism due to an autonomous nodule and multinodular goiter.
- Surgery should be reserved for those with compressive symptoms (dysphagia and shortness of breath) or suspicious of malignancy.
View source ↗